Reagenti e strumenti per immunologia, biologia cellulare e biologia molecolare
 
> Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant [9002-93-1]

Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant [9002-93-1]

Stampa Stampa
Entra

Cat# HY-Y1883-100mL

Size : 100mL

Marca : MedChemExpress


Description

Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant is a non-denaturing detergent that solubilizes lipid membranes. Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant is commonly used in laboratories and is applied to vaccines at different stages of the manufacturing process. Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant is listed as an excipient in certain vaccines including split virus influenza vaccines. Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant is a nonionic surfactant. Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant induces Apoptosis in prostate and colon cancer cell lines and reduces the infectivity of classic enveloped viruses such as WNV[1][2][3][4][5].

In Vitro

Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant (0.5%-0.05%, 1 h) reduces the infectivity of a classical enveloped virus such as West Nile virus (WNV)[3].
Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant (0.19-0.20 mM) makes the HeLa cells underwent irreversible permeabilization of the membrane and structural collapse[4].
Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant (0.01%, 1 h) induces apoptotic and necrotic death in prostate and colon cancer cell lines (PC-3, SW-620 and HT-29 cells), characterized by the typical morphological features and internucleosomal DNA fragmentation[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant Related Antibodies

Solvant et solubilité
In Vitro: 

DMSO : ≥ 100 mg/mL

*"≥" means soluble, but saturation unknown.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL; Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL; Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Pureté et documentation
Références